BlackRock’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-50,000
Closed -$1.32M 5168
2019
Q1
$1.32M Buy
+50,000
New +$1.18M ﹤0.01% 3830

Other funds holding HZNP

BlackRock's HZNP Position: Q4 2023 in Review

BlackRock sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 14,871,176 shares — an estimated $1.72B sold.

BlackRock first reported a position in HZNP in Q3 2013 and held it in 38 quarters. The position peaked at $1.72B in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • BlackRock reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • BlackRock sold 14,871,176 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $1.72B.
  • BlackRock first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2013 and held it in 38 quarters.
  • BlackRock's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.72B in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on BlackRock's 13F filing for Q4 2023, filed 13 Feb 2024.